Jame Abraham, Chairman and Professor at the Department of Hematology and Medical Oncology at Cleveland Clinic, shared a post on LinkedIn about a paper he co-authored with colleagues published in NEJM:
“In patients with high-risk, residual invasive HER2-positive breast cancer, postneoadjuvant treatment with Trastuzumab Deruxtecan (T-DXd) has shown a significantly higher likelihood of invasive disease-free survival compared to T-DM1.
The toxic effects observed were primarily gastrointestinal and hematologic. Additionally, a critical risk associated with T-DXd is interstitial lung disease, which necessitates careful monitoring and management.
Published in the New England Journal of Medicine.
TDXd could be a new standard – Grateful to all the patients and researchers around the world!”
Title: Trastuzumab Deruxtecan in Residual HER2-Positive Early Breast Cancer
Authors: Sibylle Loibl, Yeon Hee Park, Zhiming Shao, Chiun-Sheng Huang, Carlos Barrios, Jame Abraham, Aleix Prat, Naoki Niikura, Seock-Ah Im, Wei Li, Huiping Li, Yongsheng Wang, Herui Yao, Sung-Bae Kim, Cui-zhi Geng, Wuilbert Rodriguez Pantigoso, Francisco Javier Ramírez Godinez, Chuangui Song, Yuan Ching Chang, Augusto Antoniazzi, Shin-Cheh Chen, Zhigao Li, Zbigniew Nowecki, Joline Lim, Elton Mathias, Yuta Sato, Wenjing Lu, Hanan Abdel-Monem, Michael Untch, and Charles E. Geyer, Jr
You can read the Full Article in the New England Journal of Medicine.
More posts featuring Jame Abraham.
